What research can I access at Manchester Vascular Centre?

Author:Bradley Tallon

Author: Bradley Tallon

Senior Clinical Trials Coordinator

Bradley is the Senior Clinical Trials Coordinator for the Vascular, ENT, Trauma & Orthopaedics, Surgery and MVR Trials Office

When I joined the Research Team at Manchester Vascular Centre in January 2016 as a Clinical Trials Coordinator, it soon became apparent the scope of the work performed by the team there.

The surgeons operate on all manner of blood vessels throughout the body, treating many symptoms and providing therapy for a number of conditions.  As such, the aim of the team is to reflect the unique range of services offered to our patients with the research that we carry out.

Our ultimate aim is to offer patients with any vascular condition the chance to participate in a research study or clinical trial that will directly benefit them.  It is part of CMFT’s vision as a Trust to provide patients with the best experience possible when accessing healthcare, and research is one of the most important ways in which we can realise this. Last year was a great success for the Manchester Vascular Centre Research Team.  39 patients were recruited to a number of different studies.  Already in the first quarter of 2017, we have recruited 30 patients to our studies, so we are on course for an even more successful year.

What are the types of research we do?

To explain the types of research the unit conducts I have listed each of the consultant vascular surgeons specific research interests:

Mr J Vince Smyth: Carotid Artery Research

This research focuses on helping patients that have had a stroke, or are at increased risk of a stroke. Interested and eligible patients can benefit from a long and detailed follow up as we strive to find the best treatment for the narrowing of the main artery in the neck that supplies the brain with oxygen. 

Mr Tawqeer Rashid: Lower Limb Research

This research focuses on dramatically reducing the need for leg amputations by restoring the blood flow to at risk blood vessels. Our research in this area looks to find the answer to whether bypass surgery on the leg, or inflating a balloon in the artery to expand any blocked areas, is best.  We are also involved in trialling new medicines that we hope may benefit patients who have had this procedure to save their legs.

Mr David Murray: Aortic Research

This research aims to find the best treatments for patients with aneurysms in the main artery in the chest and stomach, the aorta. We are part of an exciting study that looks to find the most successful and beneficial treatment for patients with chest aneurysms, as there has never been a study to determine this before.

Professor Ferdinand Serracino-Inglott: Infection Control Research

One of the risks involved for any patient undergoing surgery is the possibility of developing an infection post-operatively. Professor Serracino-Inglott is the Infection Control lead for the Division of Surgery at CMFT and is involved in studies that reflect this interest.  We hope to understand more about the incidences of post-operative infection and reduce these accordingly.

Mr Naseer Ahmad: Lower Limb Research/Epidemiology

Mr Ahmad’s primary research interest is around vascular services as a whole. A look at the various incidences of leg amputation throughout the North West and the difference in health inequalities when compared with other areas of the UK has highlighted the need for an evaluation of vascular services and the re-designing of these services for patient benefit.

Mr Frank Bowling: Diabetic Foot Research

Along with Mr Tawqeer Rashid and Nr Naseer Ahmad, Mr Frank Bowling is part of the lower limb salvage team. Mr Bowling has extensive research experience, both in the fields of diabetes and surgery.  His work is focused around health technology and how new devices can play a part in the treatment and care of patients.

Manchester Vascular Centre is leading the way in all fields of research, especially in terms of new medical devices.  The RECELL study has enabled patients to access a brand new treatment, in the form of an innovative spray-on skin system, for diabetic foot ulcers.  Other treatments have not worked for these patients and without this new treatment option; many patients would have continued to suffer.  When treated with the RECELL device, the ulcers have started to heal.  By proving the effectiveness of this treatment and demonstrating its worth to patients, we hope that more people will be able to access RECELL.

Nothing stands still in medicine, questions are constantly being asked, and new products are constantly in development.  The VOYAGER study takes a relatively new medicine, Rivaroxaban, and asks if patients who have recently had an operation on the blood vessels in their legs will benefit from taking it.  We already know that this medicine reduces the risk of stroke, helps to restore abnormal heart rhythms and successfully thins blood that is overly thick and prone to clotting.  We at Manchester Vascular Centre want to know if it can help our patients too, which is why we give our patients the chance to help us answer this important question.

How can I find out more?

If you are a patient ask your consultant, your vascular specialist nurse or even a member of the research team directly.  We try to be as visible as possible around the Trust to make it easier for patients to get involved.

If you are a healthcare professional who would like to refer a patient on to a study, please speak to a member of our research team.

The number of studies that we are committed to is always increasing, so if there is a particular condition that you would like to see if we have a study for, then please do get in touch.

Questions that we look to answer with our research in the near future are:

  • Can we fix an aneurysm as a day-case outpatient procedure instead of a major operation?
  • Is there a better product to stop bleeding during surgery?
  • What is the most successful way to angioplasty a blocked blood vessel in the leg?

Find out more

Find out more about the Manchester Vascular Centre’s rapidly expanding research portfolio